More than 18 million people worldwide suffer from rheumatoid arthritis, including nearly 1.5 million Americans.
Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
Hoskinson Health’s rheumatology program offers diagnosis and treatment for autoimmune and arthritis conditions using in-house ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results